Maybe Aderans is further along than we think…? And how come I never encountered this website before?
I don’t know BB. I just hope it is for the good…
Thanks for posting that link BB.That’s a great website with allot of info but I really wouldn’t put money on them crossing the finish line first.
This is Ken Washneik in 2004 on HM: “It’s the Holy Grail of hair technology and we are going to be the first to get it.” Part of me hopes that Washenik and Aderans are further along than we realize, and that they’re on the cusp of curing this disease. This website surprised me, as well as the fact that they’ve been doing Phase I studies on HUMANS for 14 months now. We don’t talk much about Aderans here, but they have many millions in funds, some brilliant minds on board like Kurt Stenn, and they have a commitment for a timeframe for commercialization in 2009. Also, keep in mind Washenik has been talking about a 2009-2010 release date since 2004. I’m betting on Intercytex, but f**k I hope Aderans delivers, too!!
» Thanks for posting that link BB.That’s a great website with allot of info
» but I really wouldn’t put money on them crossing the finish line first.
» Maybe Aderans is further along than we think…? And how come I never
» encountered this website before?
»
» http://www.clinicalhairtrial.com/
From the website it looks like they are just recruiting for phase I. Am I missing something?
Cockneyninja and othes have emailed Aderans. Aderans has confirmed that they have already begun Phase I trials about a year ago. The site also states that they have started Phase I trials (but they also say they’re recruiting).
» From the website it looks like they are just recruiting for phase I. Am
» I missing something?
» This is Ken Washneik in 2004 on HM: “It’s the Holy Grail of hair
» technology and we are going to be the first to get it.” Part of me
» hopes that Washenik and Aderans are further along than we realize, and
» that they’re on the cusp of curing this disease. This website surprised
» me, as well as the fact that they’ve been doing Phase I studies on
» HUMANS for 14 months now. We don’t talk much about Aderans here,
» but they have many millions in funds, some brilliant minds on board like
» Kurt Stenn, and they have a commitment for a timeframe for
» commercialization in 2009. Also, keep in mind Washenik has been talking
» about a 2009-2010 release date since 2004. I’m betting on Intercytex, but
» f**k I hope Aderans delivers, too!!
I agree,the more solutions the merrier !
ICX will charge a fortune for their procedure if they are the only clinic that offers hm.
According to a 2004 article, Washenik said a full head of hair would cost 10,000 bucks with hm… I thought: that’s it??? Christ, when hm rolls out nobody’s going to pay 30,000 bucks for pathetically thin coverage and a 14 inch strip scar in the back…
» I agree,the more solutions the merrier !
» ICX will charge a fortune for their procedure if they are the only clinic
» that offers hm.
» According to a 2004 article, Washenik said a full head of hair would cost
» 10,000 bucks with hm… I thought: that’s it??? Christ, when hm
» rolls out nobody’s going to pay 30,000 bucks for pathetically thin
» coverage and a 14 inch strip scar in the back…
»
That’s a joke in any currency!
I hope this is the case because I really want to see strip surgery become extinct along with the psychos who perform them.
However,I don’t like publicity seeking people who boast & brag about things. It makes me believe that they are full of sh*t.Humble,reserved people like Kemp who don’t make promises or baseless claims are more trust worthy.
I don’t trust Washenik. He seems more interested in marketing and making money than anything. Credible scientists don’t go on commercials and talk shows like he does. He dosent have the scientific muscle to pull something like this off. HM isn’t easy, he’s not gonna figure it out, and he knows it. He’s just kind of hanging around waiting to see what intercytex does and then just copy it.
I get your point, and I don’t totally disagree. But keep in mind several things: 1. Washenik is by no means the only scientist at Aderans working on HM; 2. Paul Kemp has also done a lot of marketing and promotion (remember his comment about baldness being a choice by 2009?); 3. there’s no way Washenik is just waiting around for intercytex, b/c they are taking a quite different approach to hm; 4. finally, keep in mind Washenik doesn’t need as much marketing/publicity b/c Aderans is a wig and HT company so Aderans will channel in funds regardless as an insurance/preventive measure.
» I don’t trust Washenik. He seems more interested in marketing and making
» money than anything. Credible scientists don’t go on commercials and talk
» shows like he does. He dosent have the scientific muscle to pull something
» like this off. HM isn’t easy, he’s not gonna figure it out, and he knows
» it. He’s just kind of hanging around waiting to see what intercytex does
» and then just copy it.
http://www.intermarkltd.com/ClinicalTrialPressRelease.htm
LONDON - CHOSEN LOCATION FOR PIONEERING CLINICAL STUDY
Source: InterMark Associates, Ltd.
Aderans Research initiates Phase 1 clinical trial
for autologous cellular treatment of hair loss
UK plans are unveiled for the commencement of Phase 1 clinical studies for the treatment of hair loss using unique tissue engineering techniques
London, United Kingdom, July, 2006 – Aderans Research, the specialist tissue engineering research group for hair loss, has announced plans for the commencement of London based clinical studies for the treatment of hair loss using its unique tissue engineering technique, a bio engineered hair loss solution that cultivates a persons own cells to overcome the problem of insufficient hair supply and pattern baldness.
The Aderans Research proposed solution has received Guy’s and St Thomas’ and King’s hospital approvals by the East London and the City research ethics committee for the Phase 1 trial. Subjects taking part in the study will be treated at private clinics located at London Bridge hospital and Harley Street.
The treatment under study proposes to overcome a key limitation of conventional surgical hair transplantation by creating new hair growth. Current procedures are limited by one central problem – each patient has only a finite number of hair follicles for redistribution with approximately 100,000 follicles in place at birth. Thus, once hair loss starts, the head of hair that each person has at that moment in time is the most hair that they can expect for the rest of their lives.
With the Aderans Research proposed technique, clinicians may be able to grow as many of the person’s own cells as necessary to increase normal hair growth and the treatment can be repeated to ensure high quality hair restoration results.
Under the Aderans Research process, doctors use a minimally invasive biopsy procedure to remove a small amount of tissue from the scalp. Hair forming cells are extracted and allowed to multiply under tightly controlled cGMP laboratory conditions. Once sufficient new cells are formed, they are then injected into the patient’s scalp with a tiny needle.
Aderans Research, in conjunction with InterMark Associates Ltd, the medical technology consulting specialists and clinical research organisation (CRO) for the study, have identified lead investigators to initiate the clinical trials for the application of the new treatment for hair loss. Mr Chris Inglefield, a leading plastic and reconstructive surgeon, based at London Bridge Hospital, is the principal investigator and Dr Alan Kingdon, medical director of the cosmetic surgery clinic in Harley Street, London, the co-investigator. Dr Mark Lewis, director of research operations at the Eastman Dental Institute of University College London, will act as the study’s medical monitor.
Mr Chris Inglefield, commenting on the trial, said: “This unique process aims to provide hair growth for both men and women who are not catered for by current hair transplant and surgical techniques. By harvesting and expanding the hair cells to many millions, this process may be able to restore normal hair density.”
Dr. Mark Lewis added: “Although a great deal of biological research has been, and continues to be, conducted into autologous cell therapies, the number of actual patient interventions available remains low. This trial represents the cutting edge of cell engineering investigations with the subjects own hair follicle cells (comprising 2 cell types) being placed into their balding scalp.”
Robert Sexauer, managing director of InterMark Associates, said: “The Aderans cellular engineering and treatment process may emerge as a significant contribution to the expanding medical use of a person’s own cells for restorative purposes.”